Moderna Inc stock stands at EUR 196.54 with USD 87.4 billion market cap

Published on 10/09/2026 at 19:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna Inc stock was up 12.31 percent versus EUR 174.99 on October 9, 2026. The investor event is scheduled for October 24, 2026, alongside phase 3 data.

Key points in brief

Moderna Inc stock was trading at EUR 196.54 at Lang & Schwarz on October 9, 2026, plus 12.31 percent versus its EUR 174.99 prior close.
The primary Nasdaq quote was USD 220.19, with the stock 0.52 percent below its USD 221.34 52-week high.
Moderna's market capitalization was USD 87.4 billion, while Citigroup's September 30 target stood at USD 80.
The next dated company event is an investor webcast on October 24, 2026, linked to phase 3 cancer-treatment data.

Aquarellmalerei der Cambridge-Skyline mit modernen Forschungsgebäuden am Charles River — Moderna Inc. (US60770K1034) präsentiert eine stimmungsvolle Aquarell-Ansicht der Cambridge-Skyline mit modernen Biotech-Forschungsgebäuden am Flussufer, Illustration mit AI erstellt.

Moderna Inc. (ISIN US60770K1079) was trading at EUR 196.54 at Lang & Schwarz on October 9, 2026, at 7:43 p.m. CEST, plus 12.31 percent versus the EUR 174.99 prior close. The bid was EUR 196.22 and the ask was EUR 196.86, while StockAnalysis identifies Moderna as a NASDAQ-listed company under ticker MRNA.

Trading range widens

The primary Nasdaq quote stood at USD 220.19 on October 9, 2026, at 1:46 p.m. ET. Trading volume was 20,675,025 shares against an average of 17,953,867, placing current activity 15.16 percent above that average.

Moderna's primary-market 52-week range was USD 22.28 to USD 221.34 on October 9, 2026. At USD 220.19, the stock was 0.52 percent below its 52-week high, a comparison that puts the current valuation near the top of its annual range.

Valuation and targets

Moderna's market capitalization was USD 87.4 billion on October 9, 2026, and its price-to-earnings ratio was minus 27.57. The company reported 4,700 employees in its latest company profile, while its business spans messenger RNA medicines across infectious disease, oncology and rare disease programs.

According to Boerse Express on October 5, Citigroup moved Moderna from Neutral to Sell on September 30 while raising its price target from USD 60 to USD 80. The target remains USD 140.19 below the primary-market quote of USD 220.19, underscoring the gap between the cited target and the current share price.

Comparison with peers

Moderna Inc.: plus 12.31 percent, P/E minus 27.57, market capitalization USD 87.4 billion.

BioNTech (Nasdaq, USD): plus 5.50 percent, P/E minus 12.51, market capitalization USD 24.4 billion.

Pfizer (NYSE, USD): plus 1.44 percent, P/E 37.29, market capitalization USD 160.8 billion.

Next dated event

According to FinanzNachrichten on September 21, Moderna scheduled an investor webcast for October 24, 2026, alongside phase 3 data on intismeran autogene at the ESMO Congress. The event gives the market a dated pipeline milestone without changing the price and valuation figures above.

Price stays near its high

After-hours trading at Lang & Schwarz left Moderna at EUR 196.54 on October 9, 2026, with a plus 12.31 percent move versus the EUR 174.99 prior close. The Nasdaq quote of USD 220.19 and the USD 221.34 52-week high provide a separate home-market comparison.

The further course of trading is shown by the continuously updated real-time quote of Moderna Inc stock.